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Abstract. Elephantiasis neuromatosa (EN) can arise from 
a plexiform neurofibroma of the superficial and deep nerves 
developing from a hyperproliferation of the perineural 
connective tissue infiltrating adjacent fat and muscles. To 
date, the clinical association between EN and neurofibroma-
tosis type 1 (NF1) has been poorly defined, particularly with 
regard to the role of lymphatic alterations and the consequent 
lymphedema. The present study reports the clinical and 
biomolecular features of EN in a NF1 patient with the clear 
clinical diagnostic criteria of multiple cafè‑au‑lait macules, 
neurofibromas, EN, a positive family history and a novel NF1 
germline c.1541_1542del mutation. Lymphoscintigraphy 
(LS) highlighted marked dermal backflow in the affected 
limb, hypertrophy of the ipsilateral inguinal and external 
iliac lymph nodes, and a bilateral lower limb lymph flow 
delay. These data support the hypothesis that an extensive 
hyperproliferative process involving perineural connective, 
limb soft tissues, bones and the lymphatic system can be 
responsible for EN in NF1 patients, on the basis of adipocyte 
metaplasia triggered by lymphostasis and lymphedema, and 
bone overgrowth and gigantism caused by chronic hyper-
emia. LS and magnetic resonance imaging can be efficacious 
tools in the diagnosis and clinical characterization of the 
early onset of the disease.
Introduction
Neurofibromatosis type 1 (NF1) (MIM no. 162200), also 
known as von Recklinghausen disease, is clinically char-
acterized by the presence of simple, diffuse and plexiform 
neurofibromas. Plexiform neurofibromas are unencapsulated, 
poorly‑circumscribed tumors infiltrating the nerves and adja-
cent fat and muscles (1). The connective overgrowth can be 
limited to a single nerve or a plexus; in the latter case, when 
the plexus spreads to the epidermal and dermal tissues, it is 
termed molluscum fibrosum. This can occur multiple times, 
covering all body sites (including the forehead, temple, eyes, 
nape and upper lip) with the exception of the palms and 
soles (2). The plexiform neurofibroma variant, mixoglioma 
gelatiniforme, is usually soft and is located in the lower third 
of the leg, and when associated with lymphangiomatosis, it can 
give rise to elephantiasis neuromatosa (EN). EN is character-
ized by abnormal soft‑tissue hypertrophy and bone dysplasia 
together with early and excessive bone growth of the affected 
leg compared with the contralateral leg (3,4). Pachidermocele 
or dermatholysis may be associated with NF1, showing an 
overlap of skin layers in the thorax, buttocks and roots of the 
limbs.
The etiology of EN is not yet fully understood, but the 
association of primary lymphatic dysplasia with a lymphatic 
proliferative process has been proposed (5‑7).
The current study presents a case of NF1‑associated EN 
with typical clinical manifestations. Written informed consent 
was obtained from the patient.
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Case report
Case history. In January 2014, the case of a female patient 
was brought to our attention at the Department of Derma-
tology of University of Modena and Reggio Emilia (Modena, 
Italy) due to a 29‑year history of several neurofibromas and 
multiple (>6) cafè‑au‑lait macules. The patient presented 
with giant elephantiasis of the right leg, which had started 
to grow during late childhood, and had since accelerated its 
expansion in the following years (Fig. 1A). At birth, the patient 
exhibited a cafè‑au‑lait macule on the right thigh. By 1 year 
old, a semi‑liquid mass had developed at the same site. The 
lesion was noticed by the parents and showed indolent growth 
with no signs of bleeding or pain. Upon histopathological 
examination, it presented with the aspects of a lymphangioma. 
Lymphedema of the ipsilateral foot and discrepant leg lengths 
were noted successively. In the following years, the uneven leg 
growth was associated with bone proliferation, which required 
a number of osteotomies with the aim of stopping the growth. 
Conventional lymphoscintigraphy (LS) was performed to 
assess the lower limb lymphatic drainage pathway.
The family history was suggestive of NF1, as the patient's 
father exhibited macrocephaly, hypertelorism, and multiple 
cafè‑au‑lait macules and neurofibromas.
Genetic testing, magnetic resonance imaging (MRI) and 
three‑dimensional computed tomography (3D‑CT) were also 
performed.
MRI and 3D‑CT. The MRI and 3D‑CT scan study showed a 
preponderance of adipose tissue in the elephantiasic limb, 
corresponding to three‑quarters of its whole volume, in addition 
to a severe dorso‑lumbar‑sacral scoliosis with convexity on the 
left. Two central nervous system hamartomas of the pallidus 
nucleous were also identified by MRI. 3D‑CT revealed a mild 
lumbo‑sacral meningocele and giant L4 neurofibroma (Fig. 1B).
Germline mutation analysis of the NF1 gene. Genomic DNA 
was extracted from the peripheral blood of the patient and 
the patient's father using the QIAamp DNA Blood Mini kit 
(Qiagen Inc., Valencia, CA, USA), and stored at ‑20˚C until use. 
All NF1 exons were amplified by polymerase chain reaction 
with intron spanning primers, as described previously (8), and 
then analyzed with denaturing high‑performance liquid chro-
matography, as described previously (9). For each abnormal 
elution profile, genomic DNA was directly sequenced in each 
direction using a CEQ Dye‑Terminator Cycle Sequencing kit 
(Beckman Coulter Inc., Miami, FL, USA) according to the 
manufacturer's instructions.
Mutations were checked using the Mutalyzer program 
(http://www.lovd.nl/mutalyzer). NF1 germline deletion 
g.129042_129043delAG; c.1541_1542del; p.(Gln514Argfs*43) 
was found in the proband and the patient's father. To the best of 
our knowledge, this type of mutation has not previously been 
described.
Lymphedema and limb lymphatic assessment. A common tape 
measure was used to assess the limb circumferences of the 
patient. Reference circumferences were the popliteal crease, 
point zero (K), +30 cm (A), +20 cm (B) and +10 cm (C) in the 
thigh, ‑10 cm (D), ‑20 cm (E) and ‑30 cm (F) in the lower leg, 
Figure 1. (A) Clinical aspect of elephantiasis neuromatosa. (B) Severe 
dorso‑lumbar‑sacral scoliosis with convexity on the left and preponderance of 
adipose tissue in the elephantiasic limb, corresponding to three‑quarters of its 
whole volume, as detected by three‑dimensional computed tomography scan 
and magnetic resonance imaging. (C) Conventional lymphoscintigraphy per-
formed to assess the lower limb lymphatic drainage pathway: Images obtained 
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and 10 cm proximal from the tip of the first toe (G). Leg volumes 
were calculated according to these measurements (10).
Lower limb lymphatic function was assessed by LS, using 
injections of 37‑MBq 99mTc‑labeled human serum albumin. 
Injection points were in the first, second and fourth interdigital 
and retromalleolar spaces of the affected and contralateral foot. 
Image acquisition was obtained after 60 and 240 min using a 
dual head γ‑camera (Philips Healthcare, Andover, MA, USA) 
equipped with a low‑energy and high‑resolution collimator, 
and an energy peak centered on 140 KeV (window of 20%).
The criteria to define lymphatic dysfunction include delay, 
asymmetric or absent visualization of regional lymph nodes, 
and the presence of dermal backflow. Other observations include 
the visualization of asymmetric lymphatic channels, collateral 
lymphatic channels, interrupted vascular structures, and lymph 
nodes of the deep lymphatic system (i.e., popliteal lymph nodes 
following web space injection in the lower extremities) (11).
In LS, the images obtained 60 min after the injections 
showed bilateral lower limb lymph flow delay. Mild dermal 
backflow in the absence of tracer migration was observed 
in the affected lower limb, whilst one inguinal lymph node 
was observed in the left limb. Posterior images confirmed 
the findings, also visualizing a popliteal lymph node in the 
healthy (left) leg. Images acquired at 240 min showed signifi-
cant dermal backflow in the right limb, and hyperplasia and 
hypertrophy of the inguinal and external iliac lymph nodes, in 
comparison to those of the left leg (Fig. 1C).
Treatment and patient outcome. In May 2014, the patient was 
treated with surgery to reduce the volume of tissue in the leg 
region; tissue with a mass of 4.3 kg was removed. However, the 
outcome was not as good as expected due to hemorrhage during 
surgery, which prevented complete exision. Following surgery, 
the patient exhibited limited functional improvement and limb 
lightening. The patient was subsequently administered anticoag-
ulant therapy with enoxaparin (8,000 IU, daily for one year) and 
underwent regular follow up examinations every three months 
for the first year and every six months subsequently. At the time 
of writing, the patient was well with a good prognosis.
Discussion
EN is a rare clinical manifestation associated with the NF1 
phenotype. The condition should be defined as early and exces-
sive growth in the width and length of the affected limb due to 
a neoplastic proliferation of the perineural connective tissue, 
together with congenital lymphatic insufficiency and chronic 
hyperemia. While no more than 30 cases are described in the 
literature (Table I) (12‑32), the real incidence is estimated to 
be higher. The clinical expression is characterized by plexi-
form neurofibromas located in the superficial or deep nervous 
system associated with congenital lymphangiomathosis. Signs 
usually appear during the first years of life, due to lymphostasis 
and subsequent lymphedema causing adipocyte metaplasia 
of the adjacent tissues and chronic hyperemia inducing bone 
overgrowth and focal gigantism (34).
Distinct superficial dysplastic skin alterations known 
as pachidermocele or dermatholysis, histologically corre-
sponding to mixoglioma gelatiniforme, must be distinguished 
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To date, little evidence is available regarding the role of 
lymphatic alterations in the pathogenesis of EN.
Based on the bilateral lymphatic defect, the presence of 
a primary lymphatic disease in the current NF1 patient can 
be hypothesized. The disease is probably supported by a 
dysplastic‑hypertrophic condition as a result of a congenital 
alteration of the lymphatic network (35,36).
Regarding the lymph to fat transformation, it is known 
that lymphostasis due to primary and secondary lymphedema 
determines the transformation of fat cells, resulting in hyper-
trophied adipose tissue. Several studies (37‑39) have suggested 
that lymphedema leads to adipose tissue accumulation and 
fibrosis. Moreover, we believe that this process is amplified in 
NF1 and in EN due to a primary lymphatic disorder, which is 
at the base of the clinical manifestation induced by the plexi-
form neurofibroma growth.
Overall, the diagnostic criteria for NF can be improved by the 
introduction and application of novel criteria based on a wider 
case series (EN, focal gigantism, mixoglioma gelatiniforme 
and primary lymphatic disorder), leading to the early diagnosis 
of NF1, particularly in pediatric patients. LS and MRI can be 
efficacious tools in the diagnosis and clinical characterization 
of early onset cutaneous, subcutaneous and skeletal anomalies.
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